KCM
AUPH icon

Kathmere Capital Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Kathmere Capital Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$296K Buy
17,461
+6,218
+55% +$99.3K 0.02% 528
2026
Q1 		$167K Buy
+11,243
New +$164K 0.01% 592

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kathmere Capital Management's AUPH Position: Q2 2026 in Review

Kathmere Capital Management increased its Aurinia Pharmaceuticals (AUPH) stake by 55% in Q2 2026, buying an estimated $99.3K and bringing the position to 17,461 shares worth $296K. The position accounts for 0.02% of the portfolio, ranked #528.

Kathmere Capital Management first reported a position in AUPH in Q1 2026 and has held it in 2 quarters since. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Kathmere Capital Management held 17,461 shares of Aurinia Pharmaceuticals worth $296K as of Q2 2026.
  • Kathmere Capital Management bought 6,218 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $99.3K.
  • Aurinia Pharmaceuticals made up 0.02% of Kathmere Capital Management's portfolio in Q2 2026, its #528 holding.
  • Kathmere Capital Management first reported a position in Aurinia Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Kathmere Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.